Answer
No. It is a targeted monoclonal antibody that depletes CD20-positive B cells and is licensed as a disease-modifying treatment for relapsing multiple sclerosis, not as chemotherapy.
Sources for this answer
- Kesimpta 20 mg solution for injection in pre-filled pen — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.